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The treatment of several solid and hematologic malignancies with immune checkpoint 
inhibitors (against PD-1/PD-L1) has dramatically changed the cancer treatment paradigm. 
However, no checkpoint inhibitors were previously approved for the treatment of triple-
negative breast cancer (TNBC), a difficult-to-treat disease with a high unmet therapeutic 
need. Based on IMpassion130 clinical trial (NCT02425891), FDA has recently granted an 
accelerated approval for atezolizumab (TECENTRIQ®), a monoclonal antibody drug 
targeting PD-L1, plus chemotherapy (Abraxane; nab®-Paclitaxel) for the treatment of adults 
with PD-L1-positive, unresectable, locally advanced or metastatic TNBC. FDA has also 
approved the Ventana diagnostic antibody SP142 as a companion test for selecting TNBC 
patients for treatment with atezolizumab. In the present review, we briefly discuss the 
importance of this breakthrough as the first cancer immunotherapy regimen to be approved 
for the management of breast cancer. 
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Recent advances in the development of cancer immunotherapy using immune checkpoint 
inhibitors against either programmed death receptor-1 (PD-1) or its ligand PD-L1 has 
revolutionized treatment of several solid tumors (1-4). The interaction between PD-1 on T-
cells and its ligands PD-L1 and PD-L2 on cancer cells promotes T-cell exhaustion and 
conversion of T effector cells to immunosuppressive T regulatory (Treg) cells (Figure 1) (5). 
Immune checkpoint inhibitors (against either PD-1 or PD-L1) block the suppressor PD-1/PD-
L1 axis contributing to the reactivation of cytotoxic T effector cells and consequently 
enhancing the anticancer activity of the immune system (illustrated in Figure 1) (5). 
Stunning successes of monoclonal antibody-based immune checkpoint inhibitors against PD-
1/PD-L1 (e.g. nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, ipilumab) 
have been achieved in various cancers (6). These include non-small cell lung carcinoma 
(NSCLC), renal, bladder, head and neck, gastric/gastroesophageal (GEJ), microsatellite 
instable (MSI-H) colorectal, cervical, hepatocellular and Merkel cell carcinoma as well as in 
malignant melanoma (both pediatric and adult) and classical Hodgkin lymphoma (6, 7). In 
addition, an anti-PD-1 agent pembrolizumab has been approved for all solid MSI-H cancers 
regardless the histotype (“tumor agnostic approach”) (7-10).  
Triple negative breast cancer (TNBC) is a complex and highly aggressive subtype of breast 
cancer lacking estrogen (ER), progesterone (PR) and HER2 receptors, thereby making it 
difficult to treat (11). It carries the highest metastatic potential and has the poorest clinical 
outcome among all the subtypes of breast cancer (11). Due to the advances in molecular 
characterization of TNBC, various novel therapeutic targets including PARP (poly ADP 
ribose polymerase) 1 inhibitors, tyrosine kinase inhibitors, immune checkpoints, anti-
androgens and epigenetic targets have come into focus (11). 
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Although breast cancer has been initially considered a “non-immunogenic” cancer, numerous 
studies have now shown PD-L1 expression in both cancer and inflammatory cells (tumor 
infiltrating lymphocytes). PD-L1 positivity in cancer or inflammatory cells has been reported 
across the breast cancer histotypes (12-26). In particular, ER-negative breast cancers [TNBC 
and HER2-positive] have been shown to be “immunogenic” and potentially amenable for the 
trials with anti-PD-1/PD-L1 agents (12, 16, 17, 20, 26-35). TNBC is thought to have 
relatively high PD-L1 expression, predominantly in inflammatory (immune) cells and 
occasionally in cancer cells (Figure 2A-B) (14, 16-18, 20, 29-31, 36-39). A recent systematic 
review of Zhang et al. (40), based on analysis >2,500 breast cancers, revealed PD-L1 
positivity in the range 21-56% (Table 1). In such studies, the tumor proportion score (TPS) is 
defined as “the percentage of viable tumor cells showing partial or complete membrane 
staining (≥ 1+) relative to all viable tumor cells present in the sample (positive and 
negative)”, source: https://www.accessdata.fda.gov/cdrh_docs/pdf15/p150013b.pdf, 
accessed: March 10, 2019). It is noteworthy that in most PD-L1 positive breast cancers, PD-
L1 expression is not diffuse (>50% of positive cancer cells or TPS<50%) but rather focal or 
patchy and limited to a small proportion of cancer cells (14).  
There are numerous ongoing clinical trials with immune checkpoint inhibitors combined with 
other treatment modalities in breast cancer (41). Of note has been atezolizumab which 
selectively targets PD-L1 to prevent interaction with the receptors PD-1 and B7-1 (a 
costimulatory cell-surface protein) to reverse T-cell suppression. It had previously been 
approved as a single-agent for the treatment of metastatic urothelial/bladder carcinoma and 
non–small-cell lung cancer (42, 43). This monoclonal antibody drug is clinically effective 
and has a good safety profile in patients with other solid tumors (1), so was a good candidate 
for potential use in the management of patients with TNBC. The most remarkable results 
have been recently achieved in the clinical trial IMpassion130 (NCT02425891) (44). This 
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study led the Food and Drug Administration (FDA) to grant accelerated approval for 
atezolizumab (TECENTRIQ®, anti-PD-L1 agent) in combination with chemotherapy using a 
solvent-free, nanoparticle albumin-bound (nab) formulation of paclitaxel (nab®-Paclitaxel;  
Abraxane) for the treatment of patients with TNBC (Date of approval: March 8, 2019). The 
approval was based on the randomized trial involving 902 TNBC patients with unresectable, 
locally advanced and/or metastatic TNBC without prior treatment for the metastatic disease. 
Patients were randomized (1:1) to receive atezolizumab plus chemotherapy with Abraxane 
vs. placebo plus Abraxane. The possible rationale for combining the checkpoint inhibitor 
with taxane-based chemotherapy that inhibits mitosis was that it may enhance tumor-antigen 
release and antitumor responses to immune checkpoint inhibition. Additionally, solvent-free 
taxanes might also activate toll-like receptors and promote dendritic cell activity (Figure 1) 
(45, 46). 
In the IMpassion130 trial, prior to treating patients with atezolizumab, tumor samples were 
centrally assessed by immunohistochemistry for the presence of PD-L1 expression (SP142 
clone, Ventana). PD-L1 expression was assessed in tumor-infiltrating (immune) cells using 
two-tier system: “a percentage of tumor area” <1% (=PD-L1 negative) or ≥1% (=PD-L1 
positive). The study revealed that the patients whose cancers were positive for PD-L1 (~41%) 
and received atezolizumab did significantly better than those treated with nab-paclitaxel: 
Median progression-free survival (PFS) was 7.2 months with atezolizumab compared with 
5.5 months of the patients treated with placebo-nab-paclitaxel only. In the PD-L1–positive 
subgroup, the response rate was ~59% with atezolizumab–nab-paclitaxel in comparison with 
~43% in the placebo–nab-paclitaxel subgroup. Notably, 10% of the patients in the 
atezolizumab–nab-paclitaxel group achieved a complete response as compared with only 
~1% of those in the placebo–nab-paclitaxel group (44). Importantly, the atezolizumab plus 
nab-paclitaxel combination group yielded no new safety concerns as the safety profile 
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appeared consistent with the known profiles of each component drug. Indeed, the most 
common side effects with the combined treatment were hair loss, fatigue, tingling or 
numbness in the hands and feet, nausea and vomiting, diarrhea, anemia, constipation, cough, 
headache, neutropenia, and reduced appetite that were present among 20% or more of 
patients. 
One of the important findings in the IMpassion130 trial is the efficiency of combined therapy 
(immunotherapy + conventional chemotherapy). The combined treatment has its rationale at 
the molecular level as illustrated in the case of breast cancer in Figure 1. This approach has 
also been clinically verified to be successful in other cancers like NSCLC. Thus, FDA in 
September 2017 approved the first combination of chemotherapy and immunotherapy for 
patients with metastatic, non-squamous NSCLC. The approval included pembrolizumab 
(KEYTRUDA®) in combination with pemetrexed and carboplatin. The approval was based 
on results obtained in the KEYNOTE-021 Phase 2 clinical trial that demonstrated that non-
squamous NSCLC patients treated with the combination therapy exhibited a 55% therapeutic 
response rate in comparison with 29% with chemotherapy alone (47). A recent update on this 
study (24 months follow-up) confirmed the initial data with significant improvements in 
progress-free survival and objective response rate (~57% in combined group vs. 30% in 
chemotherapy group) in the patients treated with combined immunotherapy 
(pembrolizumab)-chemotherapy (pemetrexed-carboplatin) (48). More recently the FDA on 
March 18, 2019 has granted accelerated approval for the use of atezolizumab in combination 
with carboplatin and etoposide chemotherapy for the first-line treatment of adult patients with 
extensive-stage small cell lung cancer (ES-SCLC). Approval was based on the IMpower133 
(NCT02763579), a randomized (1:1), multicenter, double-blind, placebo-controlled trial in 
403 patients with ES-SCLC. Patients receiving atezolizumab with chemotherapy showed 
improved median overall survival of 12.3 months compared to 10.3 months for those on 
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placebo with chemotherapy (hazard ratio 0.70; 95% CI: 0.54, 0.91; p=0.0069). Furthermore, 
patients on the checkpoint inhibitor plus chemotherapy had a median progression-free 
survival of 5.2 months compared with 4.3 months in the placebo with chemotherapy arm of 
the trial (HR 0.77; 0.62, 0.96; p=0.0170) (49). This approval has changed the standard first-
line therapy for the first time in several decades for this cancer (50). Despite concerns over 
the cost-effectiveness of checkpoint inhibitor-based immunotherapy (51), these recent FDA 
approvals (e.g. for NSCLC, ES-SCLC and TNBC as discussed herein) have firmly 
established the use of checkpoint inhibitors together with conventional chemotherapy as a 
novel clinical paradigm for the treatment of otherwise difficult-to-treat cancers. 
It is clinically important to identify patients who are likely to respond to checkpoint inhibitor-
based immunotherapy. Although a quite difficult task given the complex tumor 
microenvironment and interactions between the cancer and various immune cells such as T-
lymphocytes, B-lymphocytes, dendritic and antigen-presenting cells (Figure 1), several 
biomarkers have nonetheless been identified to reliably predict the effectiveness of the anti-
PD-1/PD-L1 checkpoint inhibitors in cancer patients. These include PD-L1 status (the target 
protein/antigen for atezolizumab), tumor mutational burden (load) [TMB/TML], 
microsatellite instability status (MSI) and the number of tumor infiltrating lymphocytes (TIL) 
(summarized in Tables 1 and 2). PD-L1 expression in cancer or immune cells as detected by 
immunohistochemistry has been shown to be one of the most reliable predictive biomarkers 
as confirmed in the IMpassion130 (NCT02425891) study. For detection purposes, four out of 
five diagnostic antibodies have been validated as either companion or complementary 
diagnostics (Table 1). Indeed, the current FDA approval of atezolizumab in the treatment of 
TNBC applies only to patients whose breast cancers express PD-L1 in an FDA-approved test 
(i.e. the Ventana diagnostic antibody SP142).  
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This recent FDA approval of atezolizumab plus chemotherapy for the treatment of adults 
with PD-L1-positive, unresectable, locally advanced or metastatic TNBC represents the first 
cancer immunotherapy regimen to be approved for the management of breast cancer. It is 
truly a landmark therapeutic development for patients with TNBC given the limited treatment 
options available for this heterogeneous, but a highly aggressive subtype of breast cancer 
(52). Chemotherapy alone had been the mainstay of treatment for many years for TNBC and 
so the approval of this checkpoint inhibitor combination for people with PD-L1 positive 
TNBC disease fulfils an unmet medical need. Hopefully, several additional ongoing trials 
with immune checkpoint inhibitors other than atezolizumab (41) will endorse the results from 
the IMpassion130 (NCT02425891) study. Additional efforts are also required to optimize 
predictive biomarkers in TNBC (PD-L1 antibody selection/Table 1/, threshold for positivity, 
cancer vs. immune cells expression, further dissection of the breast cancer immune 
microenvironment/see Figure 1/)(53) and to maximize the effectiveness of these important 
class of immune-targeting therapeutic agents.  
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TABLE 1. A list of the available diagnostic anti-PD-L1 antibodies and their 
status in regards to the Food and Drug Administration (FDA) approval. 
 
Antibody (Manufacturer)(54) FDA Status Cancer subtype 
 















SP263 (Ventana) Complementary diagnostics Bladder cancer 
 







73-10 (Dako Agilent/Merck) Not approved Bladder cancer 
Merkel cell carcinoma 
*Companion diagnostics = “a medical device, often an in vitro device, which provides information 
that is essential for the safe and effective use of a corresponding drug or biological product.” (Source: 
FDA, accessed January 25, 2019). 
**Complementary diagnostics = “a test that aids in the benefit–risk decision–making about the use of 
the therapeutic product, where the difference in benefit–risk is clinically meaningful” (Sources: 
ASCO/American Society of Clinical Oncology/, 2016 and (55). 
NSCLC = Non-small cell lung cancer; GEJ cancer = Gastroesophageal cancer; HNSCC = Head and 






TABLE 2. The status of predictive biomarkers to immune checkpoint inhibitors 
in cancers with approved anti-PD-1/PD-L1 agents and breast cancer. 
 
 
Predictive biomarker to 
checkpoint inhibitor 
Cancer type Status in breast cancer 
 








21-56% in ER-negative 
breast cancers (TNBC and 
HER2-positive) 
 
PD-L1 (CD274) gene 
amplification (56, 57) 
Classical HL (36%) 








High tumor mutational load 









Microsatellite instability high 






Increased tumor infiltrating 
lymphocytes (TIL) 
Renal cell carcinoma 
Colorectal carcinoma 
Gastric/GEJ cancer 
Common in ER-negative 
breast cancers (TNBC and 
HER2-positive) 
*Assessed by immunohistochemistry. 
** Tumor-agnostic approach implies a treatment based on a specific genomic/molecular/ abnormality 
in a cancer, rather than its anatomic or histologic origins (60); good examples of such an approach 
include immune checkpoint inhibitors and tropomyosin kinase receptors (TRK) inhibitors (e.g. 
larotrectinib). 
TC = tumor cells; IC = inflammatory (immune) cells; ER = Estrogen receptor; GEJ = 
Gastroesophageal junction carcinoma; NSCLC = Non-small cell lung carcinoma; HNSCC = Head and 
neck squamous cell carcinoma; TNBC = Triple-negative breast cancer; RCC = Renal cell carcinoma; 








FIGURE 1. The possible mechanism of action anti-PD-1/PD-L1 drugs (e.g. 
atezolizumab) and nab-paclitaxel in metastatic triple-negative breast cancer 
(TNBC). 
i: Metastatic breast cancers are dynamic environments undergoing proliferation and 
apoptosis along with immune cell infiltration. Breast cancers are a heterogeneous 
populations which may or may not (TNBC) be influenced by ERBB2/HER2 and/or 
nuclear estrogen receptor (ER) and progesterone receptor (PR) signaling (a). 
Apoptotic tumor cells are phagocytosed, and tumor specific antigens are expressed on 
the MHC molecules by tumor infiltrating antigen presenting cells (APC) that may 
activate antigen specific cytotoxic T cell (CTL) responses by engaging their T cell 
receptors. Costimulatory signals through B7 on APCs and CD28 on T cells are 
necessary for CTL differentiation and proliferation. T cell express Program death 
16 
 
ligand-1 (PD-L1) and its receptor PD-1. The interaction of PD-L1 with B7.1 
suppresses T cell differentiation into CTL (b). Metastatic TNBC express PD-L1 in 
abundance. The engagement of PD-L1 with PD-1 blocks CTL effector function 
allowing unchecked tumor progression (c).  
ii: Metastatic TNBC positive for PD-L1 respond to combination therapy with 
Atezolizumab (monoclonal anti-PD-L1 antibody) and Abraxane (nab-Paclitaxel) (a). 
Abraxane enhances expression of tumor specific antigens and induction of apoptosis 
(G2/M phase arrest) thereby facilitating antigen presentation via APCs (b). APCs are 
activated via nab-Paclitaxel and enhance Toll like receptor (TLR) expression 
contributing to efficient antigen presentation as well as co-stimulation by B7 family 
(c). Suppressive signal in activating T cells is inhibited as Atezolizumab blocks the 
interaction of PD-L1 with B7.1. Thus augmenting signal induction for activation, 
differentiation and proliferation of tumor specific CTL clones (d). Metastatic TNBC 
express PD-L1 in abundance. Disrupting the engagement of PD-L1 with its receptor 
PD-1 by anti-PD-L1 antibody allows CTLs to secrete perforins that make holes in 
the target cell membrane allowing granzymes to enter and induce caspase-dependent 









FIGURE 2. PD-L1 as a biomarker for TNBC. 
(A): Hematoxylin and Eosin (H&E) slide of the high-grade, triple-negative breast 
cancer (TNBC) not otherwise specified (NOS) with abundant tumor infiltrating 
lymphocytes (TILs) (10x); (B) TILs were strongly positive for PD-L1 by 
immunohistochemistry (clone SP142, Ventana). Note the lack of PD-L1 expression in 
the cancer cells (10x). 
 
 
